GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BioCardia Inc (NAS:BCDA) » Definitions » Cyclically Adjusted PS Ratio

BioCardia (BioCardia) Cyclically Adjusted PS Ratio : 0.91 (As of Jun. 06, 2024)


View and export this data going back to 1996. Start your Free Trial

What is BioCardia Cyclically Adjusted PS Ratio?

As of today (2024-06-06), BioCardia's current share price is $4.29. BioCardia's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 was $4.69. BioCardia's Cyclically Adjusted PS Ratio for today is 0.91.

The historical rank and industry rank for BioCardia's Cyclically Adjusted PS Ratio or its related term are showing as below:

BCDA' s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 0.12   Med: 26.43   Max: 275.4
Current: 0.94

During the past years, BioCardia's highest Cyclically Adjusted PS Ratio was 275.40. The lowest was 0.12. And the median was 26.43.

BCDA's Cyclically Adjusted PS Ratio is ranked better than
85.91% of 504 companies
in the Biotechnology industry
Industry Median: 5.525 vs BCDA: 0.94

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

BioCardia's adjusted revenue per share data for the three months ended in Mar. 2024 was $0.033. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is $4.69 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


BioCardia Cyclically Adjusted PS Ratio Historical Data

The historical data trend for BioCardia's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioCardia Cyclically Adjusted PS Ratio Chart

BioCardia Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 11.49 11.88 6.61 6.60 2.12

BioCardia Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6.10 8.36 1.35 2.12 1.30

Competitive Comparison of BioCardia's Cyclically Adjusted PS Ratio

For the Biotechnology subindustry, BioCardia's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BioCardia's Cyclically Adjusted PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BioCardia's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where BioCardia's Cyclically Adjusted PS Ratio falls into.



BioCardia Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

BioCardia's Cyclically Adjusted PS Ratio for today is calculated as

Cyclically Adjusted PS Ratio=Share Price/ Cyclically Adjusted Revenue per Share
=4.29/4.69
=0.91

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BioCardia's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, BioCardia's adjusted Revenue per Share data for the three months ended in Mar. 2024 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=0.033/131.7762*131.7762
=0.033

Current CPI (Mar. 2024) = 131.7762.

BioCardia Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201406 0.739 100.560 0.968
201409 0.676 100.428 0.887
201412 0.901 99.070 1.198
201503 0.958 99.621 1.267
201506 0.880 100.684 1.152
201509 0.852 100.392 1.118
201512 0.951 99.792 1.256
201603 1.049 100.470 1.376
201606 1.000 101.688 1.296
201609 38.732 101.861 50.107
201612 -18.493 101.863 -23.924
201703 0.484 102.862 0.620
201706 0.396 103.349 0.505
201709 0.459 104.136 0.581
201712 0.353 104.011 0.447
201803 0.703 105.290 0.880
201806 0.845 106.317 1.047
201809 0.296 106.507 0.366
201812 0.359 105.998 0.446
201903 0.763 107.251 0.937
201906 0.266 108.070 0.324
201909 0.483 108.329 0.588
201912 0.475 108.420 0.577
202003 0.084 108.902 0.102
202006 0.053 108.767 0.064
202009 0.040 109.815 0.048
202012 0.052 109.897 0.062
202103 0.042 111.754 0.050
202106 0.061 114.631 0.070
202109 0.721 115.734 0.821
202112 0.069 117.630 0.077
202203 0.053 121.301 0.058
202206 0.828 125.017 0.873
202209 0.178 125.227 0.187
202212 0.087 125.222 0.092
202303 0.048 127.348 0.050
202306 0.032 128.729 0.033
202309 0.248 129.860 0.252
202312 0.009 129.419 0.009
202403 0.033 131.776 0.033

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


BioCardia  (NAS:BCDA) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


BioCardia Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of BioCardia's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


BioCardia (BioCardia) Business Description

Industry
Traded in Other Exchanges
Address
320 Soquel Way, Sunnyvale, CA, USA, 94085
BioCardia Inc is a clinical stage regenerative medicine company. It is developing therapeutics for cardiovascular and pulmonary diseases with large unmet medical needs. The company is developing comprehensive biotherapeutic candidates for cardiac regenerative medicine namely CardiAMP and CardiALLO, with a focus on heart failure resulting from a heart attack.
Executives
Frost Phillip Md Et Al 10 percent owner 4400 BISCAYNE BLVD, MIAMI FL 33137-3227
Bill Facteau director C/O BIOCARDIA, INC., 320 SOQUEL WAY, SUNNYVALE CA 94085
Frost Gamma Investments Trust 10 percent owner 4400 BISCAYNE BLVD, MIAMI FL 33137
Krisztina M Zsebo director C/O CELLADON CORPORATION, 12760 HIGH BLUFF DRIVE, SUITE 240, SAN DIEGO CA 92130
Edward M Gillis officer: Senior Vice President, Devices C/O BIOCARDIA, INC., 125 SHOREWAY ROAD, SUITE B, SAN CARLOS CA 94070
Andrew Scott Blank director C/O BIOCARDIA, INC., 125 SHOREWAY ROAD, SUITE B, SAN CARLOS CA 94070
Jim L. Allen director C/O BIOCARDIA, INC., 125 SHOREWAY ROAD, SUITE B, SAN CARLOS CA 94070
Simon H Stertzer director C/O BIOCARDIA, INC., 125 SHOREWAY DRIVE, SUITE B, SAN CARLOS CA 94070
Peter Altman director, officer: President and CEO C/O BIOCARDIA INC, 125 SHOREWAY ROAD SUITE B, SAN CARLOS CA 94070
Stertzer Family Trust 10 percent owner C/O BIOCARDIA INC, 125 SHOREWAY ROAD SUITE B, SAN CARLOS CA 94070
Kimberly Stertzer 10 percent owner C/O BIOCARDIA INC, 125 SHOREWAY ROAD SUITE B, SAN CARLOS CA 94070
David Mcclung officer: VP of Finance C/O BIOCARDIA, INC., 125 SHOREWAY ROAD, SUITE B, SAN CARLOS CA 94070
Allan R Tessler director C/O EPOCH HOLDING CORPORATION, 640 FIFTH AVENUE, NEW YORK, NY 10019
Richard T Allen officer: VP, Quality Assurance C/O BIOCARDIA, INC., 125 SHOREWAY ROAD, SUITE B, SAN CARLOS CA 94070
Thomas Quertermous director C/O BIOCARDIA INC, 125 SHOREWAY ROAD SUITE B, SAN CARLOS CA 94070

BioCardia (BioCardia) Headlines

From GuruFocus

BioCardia Announces $3.6 Million Private Placement of Common Stock

By Value_Insider Value_Insider 12-15-2022